Editas Medicine Inc (NASDAQ:EDIT) Shares Sold by Great West Life Assurance Co. Can
Great West Life Assurance Co. Can lowered its holdings in shares of Editas Medicine Inc (NASDAQ:EDIT) by 73.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,454 shares of the company’s stock after selling 3,932 shares during the period. Great West Life Assurance Co. Can’s holdings in Editas Medicine were worth $33,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of EDIT. Commonwealth Equity Services LLC boosted its stake in Editas Medicine by 2.8% during the 2nd quarter. Commonwealth Equity Services LLC now owns 30,752 shares of the company’s stock worth $760,000 after purchasing an additional 850 shares during the period. AE Wealth Management LLC acquired a new stake in Editas Medicine during the 2nd quarter worth $482,000. Carnegie Capital Asset Management LLC acquired a new stake in Editas Medicine during the 2nd quarter worth $989,000. Steward Partners Investment Advisory LLC acquired a new stake in Editas Medicine during the 2nd quarter worth $27,000. Finally, Creative Planning boosted its stake in Editas Medicine by 26.6% during the 2nd quarter. Creative Planning now owns 33,564 shares of the company’s stock worth $830,000 after purchasing an additional 7,060 shares during the period. Hedge funds and other institutional investors own 82.73% of the company’s stock.
A number of analysts recently weighed in on the stock. Chardan Capital reiterated a “buy” rating and set a $55.00 price target on shares of Editas Medicine in a research note on Thursday, July 25th. BidaskClub cut shares of Editas Medicine from a “sell” rating to a “strong sell” rating in a research note on Thursday, October 10th. ValuEngine cut shares of Editas Medicine from a “buy” rating to a “hold” rating in a research note on Friday, October 25th. Finally, Morgan Stanley set a $29.00 price target on shares of Editas Medicine and gave the stock a “hold” rating in a research note on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the company. Editas Medicine currently has an average rating of “Hold” and an average target price of $35.50.
Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.69) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.59) by ($0.10). The firm had revenue of $2.33 million for the quarter, compared to analysts’ expectations of $6.88 million. Editas Medicine had a negative return on equity of 47.46% and a negative net margin of 412.70%. The firm’s quarterly revenue was down 68.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.82) EPS. As a group, equities analysts predict that Editas Medicine Inc will post -2.64 earnings per share for the current year.
In other Editas Medicine news, CEO Cynthia Collins sold 5,193 shares of the company’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $25.83, for a total transaction of $134,135.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.94% of the stock is currently owned by corporate insiders.
Editas Medicine Profile
Editas Medicine, Inc operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas.
See Also: Penny Stocks, Risk and Reward Factors
Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine Inc (NASDAQ:EDIT).
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.